Arrowhead Pharmaceuticals Announces Fiscal 2026 Second Quarter Results Webcast
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced it will host a webcast and conference call to discuss its financial results for the fiscal 2026 second quarter ended March 31, 2026. The event is scheduled for May 7, 2026, at 4:30 p.m. ET.
Investors and analysts can access the live audio webcast through the Events and Presentations section of the company’s Investor Relations website. A replay will be available approximately two hours after the conclusion of the live event. For those wishing to participate in the conference call, registration is required via the provided link to receive dial-in details and a personal identification number.
The company develops medicines targeting intractable diseases by utilizing RNA interference (RNAi) mechanisms to silence disease-causing genes. Its portfolio includes clinical and commercial RNAi therapeutics built upon the targeted RNAi molecule (TRiM™) platform, designed to precisely silence genes in various tissues such as liver, lung, muscle, adipose and central nervous system.
Arrowhead Pharmaceuticals focuses on advancing potential best-in-class and first-in-class RNAi treatments for conditions with significant unmet medical needs, emphasizing timely progress for patient benefit.
For additional information, visit the company’s official website or follow its social media channels on X (formerly Twitter), LinkedIn, Facebook, and Instagram.
Arrowhead Pharmaceuticals Announces Fiscal 2026 Second Quarter Results Webcast
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced it will host a webcast and conference call to discuss its financial results for the fiscal 2026 second quarter ended March 31, 2026. The event is scheduled for May 7, 2026, at 4:30 p.m. ET.
Investors and analysts can access the live audio webcast through the Events and Presentations section of the company’s Investor Relations website. A replay will be available approximately two hours after the conclusion of the live event. For those wishing to participate in the conference call, registration is required via the provided link to receive dial-in details and a personal identification number.
The company develops medicines targeting intractable diseases by utilizing RNA interference (RNAi) mechanisms to silence disease-causing genes. Its portfolio includes clinical and commercial RNAi therapeutics built upon the targeted RNAi molecule (TRiM™) platform, designed to precisely silence genes in various tissues such as liver, lung, muscle, adipose, and central nervous system.
Arrowhead Pharmaceuticals focuses on advancing potential best-in-class and first-in-class RNAi treatments for conditions with significant unmet medical needs, emphasizing timely progress for patient benefit.
For additional information, visit the company’s official website or follow its social media channels on X (formerly Twitter), LinkedIn, Facebook, and Instagram.